The role of immune modulation in cancer - Professor Angus Dalgleish (2021 Conference) (LDN, low dose naltrexone)

History, Pharmacology and Mechanism - Stephen Dickson, BSC (hons) MRPharmS (2021 Conference) (LDN, low dose naltrexone)

LDN Research Trust 2021 Conference - Friday Morning

Angus Dalgleish, MD - The Role of Non-Cytotoxic Drugs in the Management of Cancer (2017 Conference) (LDN, low dose naltrexone)

Angus Dalgleish, MD - The Role of LDN in the Management of Cancer (2017 Conference) (LDN, low dose naltrexone)

Prof. Angus Dalgleish: Well, I'm going to talk about LDN and cancer, and I'm coming from a very different, way of doing things. I was trained in some of my research at the Institute of Cancer Research, where you basically design drugs, put them in mice.

Angus Dalgleish, MD - The role of LDN in cancer management (2019 Conference) (LDN, low dose naltrexone)

Olga Cortez, MD - LDN Use in Women's Health II (2019 Conference) (LDN, low dose naltrexone)

Nasha Winters, ND - Using LDN to Quell the Over-Reactive Autoimmune Conditions Triggered by Many of Today's Cancer Drugs (2019 Conference) (LDN, low dose naltrexone)

Dr Akbar Khan's LDN 2019 Conference Presentation

Low Dose Naltrexone (LDN) vs. Chemotherapy: One “Unproven” Therapy Against Another?

Stephen Dickson, BSC (hons) MRPharmS - Mechanism of Action of Low Dose Naltrexone (2019 Conference) (LDN, low dose naltrexone)

LDN 2019 Conference - Saturday Morning Q&A (2019 Conference) (LDN, low dose naltrexone)

Presentations on the below and questions were asked in relation to: